Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study

Conditions: Breast Cancer Interventions: Drug: T-DM1 adjuvant Sponsors: Regina Elena Cancer Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials